申请人:Industrial Technology Research Institute
公开号:US10233212B2
公开(公告)日:2019-03-19
A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.
本发明提供了式 (I) 的化合物或其药学上可接受的盐或溶液。在式 (I) 中,R1、R2 和 R3 各自独立地为氢、氨基、硝基、卤素、羟基、C1-C6 烷氧基、羧酸、C1-C6 烷氧羰基、C1-C6 氨基、C1-C6 氨基羰基、C1-C6 烷基、支链 C1-C6 烷基、C1-C6 环烷基、C1-C6 杂环基、芳基或杂芳基,条件是 R1 和 R3 中至少有一个是氨基。还提供了包括该化合物的连接体-药物和配体-药物共轭物。